Multiple Myeloma

>

Latest News

Cilta-Cel Shows Promising OS Improvement in Lenalidomide-Refractory Multiple Myeloma
Cilta-Cel Shows Promising OS Improvement in Lenalidomide-Refractory Multiple Myeloma

July 17th 2024

Ciltacabtagene autoleucel demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory multiple myeloma refractory to lenalidomide.

Linvoseltamab Leads to Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma
Linvoseltamab Leads to Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma

June 28th 2024

Insights on Evolving Treatment Strategies for Multiple Myeloma
Insights on Evolving Treatment Strategies for Multiple Myeloma

June 19th 2024

Anemia May Not Weaken Benefit of Ruxolitinib for Myelofibrosis
Anemia May Not Weaken Benefit of Ruxolitinib for Myelofibrosis

June 16th 2024

Lower Basal Inflammation, Tumor Burden Linked to PFS Improvements With Ide-Cel in Myeloma
Lower Basal Inflammation, Tumor Burden Linked to PFS Improvements With Ide-Cel in Myeloma

June 14th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.